Les nouveaux antibiotiques respiratoires (télithromycine [KETEK], moxifloxacine [AVELOX]) ... pour quoi et pour qui ?

Table of Contents

Les nouveaux antibiotiques respiratoires(télithromycine [KETEK], moxifloxacine [AVELOX])pour quoi et pour qui ?

Plan de l’exposé

Discovery

Why a new “pneumococcal killer” macrolide ?

PPT Slide

How does erythromycin act … and fail in pneumococci ...

Narbomycin ...

From narbomycin to HMR 3004 (the first ketolide)...

Telithromycin (RU66647/HMR 3647): the final product ...

In vitro activity of telithromycin vs erythromycin as submitted to the FDA (April 2001)

Pharmacokinetics of telithromycin as submitted to the FDA (April 2001)

Pharmacodynamics of telithromycin (as based on FDA submission; april 2001)

Discovery

Fluoroquinolones: the issues ...

Fluorqouinolones: how to improve activityand control (some) toxicity ...

Moxifloxacin (BAY 12-8039) ...

Moxifloxacin activity as submitted to the FDA...

Pharmacokinetics of moxifloxacinas submitted to the FDA

Pharmacodynamics of moxifloxacin(as based on FDA submission)

Which indications in Europe … and in Belgium * ?

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Conclusions of the "Commission de transparence" for telithromycin (1/3) *

Which are the sensivities of S. pneumoniae towards telithromycin in Belgium in 2000 ?

Conclusions of the "Commission de transparence" for telithromycin (2/3) *

Conclusions of the "Commission de transparence" for telithromycin (3/3) *

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Review of the clinical studies submitted to the Belgian "Commission de transparence"

Conclusions of the "Commission de transparence" for moxifloxacin (1/2) *

Which are the sensitivities of S. pneumoniae towards moxifloxacin in Belgium in 2002 ?

Conclusions of the "Commission de transparence" for moxifloxacin (1/2) *

Pour quoi et pour qui ?

Pour quoi et pour qui ?

Price comparisons (in Belgium) ...

A bit of pharmacoeconomics ...

Please, ask questions ...

Email: seminf@facm.ucl.ac.be

Home Page: http://www.md.ucl.ac.be/seminfect/resume.htm

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of the organisers of the 'Séminaire de Pathologie Infectieuse'. Please, adress your request to <seminf@facm.ucl.ac.be>